Amylyx Pharma $AMLX reported Q3 2026 EPS of -$0.38, missing the -$0.37 estimate by 2.7%. Revenue of $0 missed the $41,600 estimate by 100.0%.
https://fundspec.ai/s/AMLX/earnings
Track what company insiders are actually buying and selling.
https://fundspec.ai/s/AMLX/earnings
Track what company insiders are actually buying and selling.
November 5, 2026 at 12:06 PM
Amylyx Pharma $AMLX reported Q3 2026 EPS of -$0.38, missing the -$0.37 estimate by 2.7%. Revenue of $0 missed the $41,600 estimate by 100.0%.
https://fundspec.ai/s/AMLX/earnings
Track what company insiders are actually buying and selling.
https://fundspec.ai/s/AMLX/earnings
Track what company insiders are actually buying and selling.
#AMLX Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
https://www.stocktitan.net/news/AMLX/amylyx-pharmaceuticals-reports-third-quarter-2026-financial-6hbk5jn6vamo.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AMLX/amylyx-pharmaceuticals-reports-third-quarter-2026-financial-6hbk5jn6vamo.html?utm_source=stocktitan-bluesky&utm_medium=social
Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 5, 2026 at 12:00 PM
#AMLX Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
https://www.stocktitan.net/news/AMLX/amylyx-pharmaceuticals-reports-third-quarter-2026-financial-6hbk5jn6vamo.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AMLX/amylyx-pharmaceuticals-reports-third-quarter-2026-financial-6hbk5jn6vamo.html?utm_source=stocktitan-bluesky&utm_medium=social
Amylyx Pharmaceuticals: Q3 net loss $45.5M, cash $768.1M; avexitide NDA targeted by year-end; LUCIDITY data at ObesityWeek Nov 15.
#$AMLX FAQ + PDF report: www.merlintrader.com/amylyx-pharm...
#$AMLX FAQ + PDF report: www.merlintrader.com/amylyx-pharm...
November 5, 2026 at 4:34 PM
Amylyx Pharmaceuticals: Q3 net loss $45.5M, cash $768.1M; avexitide NDA targeted by year-end; LUCIDITY data at ObesityWeek Nov 15.
#$AMLX FAQ + PDF report: www.merlintrader.com/amylyx-pharm...
#$AMLX FAQ + PDF report: www.merlintrader.com/amylyx-pharm...
🚨 $AMLX
On November 5, 2026, Amylyx Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K . The information provided in this Form 8-K, incl...
On November 5, 2026, Amylyx Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K . The information provided in this Form 8-K, incl...
SEC Filing: AMLX
Click to view the official SEC document.
www.sec.gov
November 5, 2026 at 12:07 PM
🚨 $AMLX
On November 5, 2026, Amylyx Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K . The information provided in this Form 8-K, incl...
On November 5, 2026, Amylyx Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K . The information provided in this Form 8-K, incl...
Amylyx #$AMLX will meet investors at two conferences.
Guggenheim on Nov 9 at 9:30 a.m. ET and Stifel on Nov 10 at 3:20 p.m. ET.
Shares closed at $28.04 Mon: below SMA50, above SMA200, RSI 47.
Hub: www.merlintrader.com/amylyx-pharm...
Not investment advice.
Guggenheim on Nov 9 at 9:30 a.m. ET and Stifel on Nov 10 at 3:20 p.m. ET.
Shares closed at $28.04 Mon: below SMA50, above SMA200, RSI 47.
Hub: www.merlintrader.com/amylyx-pharm...
Not investment advice.
AMLX Stock: Amylyx Pharmaceuticals News
Amylyx Pharmaceuticals stock news: avexitide and clinical development, financial resources, milestones and the risks to execution and funding.
www.merlintrader.com
November 3, 2026 at 5:49 PM
Amylyx #$AMLX will meet investors at two conferences.
Guggenheim on Nov 9 at 9:30 a.m. ET and Stifel on Nov 10 at 3:20 p.m. ET.
Shares closed at $28.04 Mon: below SMA50, above SMA200, RSI 47.
Hub: www.merlintrader.com/amylyx-pharm...
Not investment advice.
Guggenheim on Nov 9 at 9:30 a.m. ET and Stifel on Nov 10 at 3:20 p.m. ET.
Shares closed at $28.04 Mon: below SMA50, above SMA200, RSI 47.
Hub: www.merlintrader.com/amylyx-pharm...
Not investment advice.
#$AMLX weekly close $28.86 (+6.1% w/w), below SMA50 $30.89 / above SMA200 $20.08, RSI 51.9. Support $26.04, resistance $30.00.
New hub updated: www.merlintrader.com/amylyx-pharm...
New hub updated: www.merlintrader.com/amylyx-pharm...
November 1, 2026 at 5:38 PM
#$AMLX weekly close $28.86 (+6.1% w/w), below SMA50 $30.89 / above SMA200 $20.08, RSI 51.9. Support $26.04, resistance $30.00.
New hub updated: www.merlintrader.com/amylyx-pharm...
New hub updated: www.merlintrader.com/amylyx-pharm...
Las Bolsas europeas abren en rojo tras los disturbios en Francia
➡️ https://l.euronews.com/amlX
➡️ https://l.euronews.com/amlX
October 19, 2026 at 11:51 AM
Las Bolsas europeas abren en rojo tras los disturbios en Francia
➡️ https://l.euronews.com/amlX
➡️ https://l.euronews.com/amlX
Hyperinsulinism: $RZLT $AMLX ZEAL(CPH) 128940(KOSPI)
Tumor versus congenital HI; catalyst timing and trial comparability. ZEAL and 128940 are non-US listings.
https://www.merlintrader.com/rzlt-amlx-zealand-hanmi-hyperinsulinism-catalyst-comparison/
Tumor versus congenital HI; catalyst timing and trial comparability. ZEAL and 128940 are non-US listings.
https://www.merlintrader.com/rzlt-amlx-zealand-hanmi-hyperinsulinism-catalyst-comparison/
Hyperinsulinism: $RZLT $AMLX ZEAL(CPH) 128940(KOSPI)
Rezolute, Amylyx, Zealand and Hanmi are not interchangeable hyperinsulinism trades. The comparison separates tumor and congenital disease, trial endpoints, regulatory uncertainty and financing. ZEAL is Copenhagen-listed; Hanmi 128940 is Korea-listed, not a US ticker.
www.merlintrader.com
October 11, 2026 at 9:29 AM
Hyperinsulinism: $RZLT $AMLX ZEAL(CPH) 128940(KOSPI)
Tumor versus congenital HI; catalyst timing and trial comparability. ZEAL and 128940 are non-US listings.
https://www.merlintrader.com/rzlt-amlx-zealand-hanmi-hyperinsulinism-catalyst-comparison/
Tumor versus congenital HI; catalyst timing and trial comparability. ZEAL and 128940 are non-US listings.
https://www.merlintrader.com/rzlt-amlx-zealand-hanmi-hyperinsulinism-catalyst-comparison/
Amylyx (#$AMLX) will present Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia at ObesityWeek on Nov. 15. Topline was announced in August. Avexitide is not approved.
prismmarketview.com/amylyx-sets-...
prismmarketview.com/amylyx-sets-...
October 6, 2026 at 5:39 PM
Amylyx (#$AMLX) will present Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia at ObesityWeek on Nov. 15. Topline was announced in August. Avexitide is not approved.
prismmarketview.com/amylyx-sets-...
prismmarketview.com/amylyx-sets-...
🚨 $AMLX
GEORGE MILNE, a Director, filed a notice of intent to sell 100,000 shares of common stock, valued at approximately $2,779,000.00, on 10/05/2026.
GEORGE MILNE, a Director, filed a notice of intent to sell 100,000 shares of common stock, valued at approximately $2,779,000.00, on 10/05/2026.
SEC Filing: AMLX
Click to view the official SEC document.
www.sec.gov
October 5, 2026 at 9:44 PM
🚨 $AMLX
GEORGE MILNE, a Director, filed a notice of intent to sell 100,000 shares of common stock, valued at approximately $2,779,000.00, on 10/05/2026.
GEORGE MILNE, a Director, filed a notice of intent to sell 100,000 shares of common stock, valued at approximately $2,779,000.00, on 10/05/2026.
Amylyx (#$AMLX): Positive LUCIDITY, Avexitide NDA Planned by Year-End
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/amylyx-pharm...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/amylyx-pharm...
September 23, 2026 at 10:01 PM
Amylyx (#$AMLX): Positive LUCIDITY, Avexitide NDA Planned by Year-End
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/amylyx-pharm...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/amylyx-pharm...
📉 Insider Cluster Sell
5 insiders at Amylyx Pharmaceuticals, Inc. ($AMLX) sold $2.9M in shares over 7 days.
https://earningsfeed.com/companies/1658551-amlx-amylyx-pharmaceuticals-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_sell&utm_content=automated_signal
5 insiders at Amylyx Pharmaceuticals, Inc. ($AMLX) sold $2.9M in shares over 7 days.
https://earningsfeed.com/companies/1658551-amlx-amylyx-pharmaceuticals-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_sell&utm_content=automated_signal
September 14, 2026 at 8:05 PM
📉 Insider Cluster Sell
5 insiders at Amylyx Pharmaceuticals, Inc. ($AMLX) sold $2.9M in shares over 7 days.
https://earningsfeed.com/companies/1658551-amlx-amylyx-pharmaceuticals-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_sell&utm_content=automated_signal
5 insiders at Amylyx Pharmaceuticals, Inc. ($AMLX) sold $2.9M in shares over 7 days.
https://earningsfeed.com/companies/1658551-amlx-amylyx-pharmaceuticals-inc?utm_source=bluesky&utm_medium=social&utm_campaign=cluster_sell&utm_content=automated_signal
🚨 $AMLX
On September 8, 2026, Amylyx Pharmaceuticals, Inc. entered into a Manufacturing and Supply Agreement with Bachem Americas, Inc. and on September 1, 2026, the Company entered into a term sheet with Polypeptide Group AG , pursuant to which Bachem and Polypeptide, respectively, will manufact...
On September 8, 2026, Amylyx Pharmaceuticals, Inc. entered into a Manufacturing and Supply Agreement with Bachem Americas, Inc. and on September 1, 2026, the Company entered into a term sheet with Polypeptide Group AG , pursuant to which Bachem and Polypeptide, respectively, will manufact...
SEC Filing: AMLX
Click to view the official SEC document.
www.sec.gov
September 8, 2026 at 8:55 PM
🚨 $AMLX
On September 8, 2026, Amylyx Pharmaceuticals, Inc. entered into a Manufacturing and Supply Agreement with Bachem Americas, Inc. and on September 1, 2026, the Company entered into a term sheet with Polypeptide Group AG , pursuant to which Bachem and Polypeptide, respectively, will manufact...
On September 8, 2026, Amylyx Pharmaceuticals, Inc. entered into a Manufacturing and Supply Agreement with Bachem Americas, Inc. and on September 1, 2026, the Company entered into a term sheet with Polypeptide Group AG , pursuant to which Bachem and Polypeptide, respectively, will manufact...
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Eli Lilly (LLY -0.13%) was the second company to market a GLP-1 drug. That's important to keep in mind as you look at the competitive landscape for this new class of weight-loss drugs. In some ways, investors do need to worry that…
Eli Lilly (LLY -0.13%) was the second company to market a GLP-1 drug. That's important to keep in mind as you look at the competitive landscape for this new class of weight-loss drugs. In some ways, investors do need to worry that…
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Eli Lilly (LLY -0.13%) was the second company to market a GLP-1 drug. That's important to keep in mind as you look at the competitive landscape for this new class of weight-loss drugs. In some ways, investors do need to worry that companies like Amylyx (AMLX -6.56%) are developing next-generation GLP-1 drugs. New drugs are a threat to Eli Lilly's business.
ytvmarketnews.com
August 30, 2026 at 4:43 PM
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Eli Lilly (LLY -0.13%) was the second company to market a GLP-1 drug. That's important to keep in mind as you look at the competitive landscape for this new class of weight-loss drugs. In some ways, investors do need to worry that…
Eli Lilly (LLY -0.13%) was the second company to market a GLP-1 drug. That's important to keep in mind as you look at the competitive landscape for this new class of weight-loss drugs. In some ways, investors do need to worry that…
RT @tradesviz: Top 6 from linreg + CCI (US): $AGQ $ALB $ALSN $AMLX $AU $AUGO. What's on your watchlist today? EZstockscreener gets you market-ready in seconds with its advanced query system.
August 26, 2026 at 3:02 PM
RT @tradesviz: Top 6 from linreg + CCI (US): $AGQ $ALB $ALSN $AMLX $AU $AUGO. What's on your watchlist today? EZstockscreener gets you market-ready in seconds with its advanced query system.
8KSpy alerted on the $AMLX filing. Now +80%.
Previously flagged: $RFAI $DTCX $CAN
Never miss a filing: https://8KSpy.com
Previously flagged: $RFAI $DTCX $CAN
Never miss a filing: https://8KSpy.com
August 23, 2026 at 1:52 PM
8KSpy alerted on the $AMLX filing. Now +80%.
Previously flagged: $RFAI $DTCX $CAN
Never miss a filing: https://8KSpy.com
Previously flagged: $RFAI $DTCX $CAN
Never miss a filing: https://8KSpy.com
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company? - BeyondLink
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has released topline results from the Phase 3 LUCIDITY trial of avexitide on August 18, 2026. Shares closed Monday
beyondlink.live
August 23, 2026 at 4:26 AM
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
Post-bariatric hypoglycemia affects an estimated 160,000 people in the US after gastric bypass surgery, and no FDA-approved treatment exists. Amylyx's $AMLX avexitide cut severe hypoglycemic events by 55% versus placebo (p=0.000003) in a Phase 3 trial. FDA filing planned by year-end.
August 21, 2026 at 10:11 AM
Post-bariatric hypoglycemia affects an estimated 160,000 people in the US after gastric bypass surgery, and no FDA-approved treatment exists. Amylyx's $AMLX avexitide cut severe hypoglycemic events by 55% versus placebo (p=0.000003) in a Phase 3 trial. FDA filing planned by year-end.
🚨 $AMLX
Bedrosian Camille L (Chief Medical Officer) reported special transactions (Non-P/S).
Bedrosian Camille L (Chief Medical Officer) reported special transactions (Non-P/S).
SEC Filing: AMLX
Click to view the official SEC document.
www.sec.gov
August 21, 2026 at 1:02 AM
🚨 $AMLX
Bedrosian Camille L (Chief Medical Officer) reported special transactions (Non-P/S).
Bedrosian Camille L (Chief Medical Officer) reported special transactions (Non-P/S).